Iron Deficiency and FGF23 Regulation in CKD and HF

Completed

Conditions studied: Chronic Kidney Diseases, Chronic Heart Failure, Iron Deficiency Anemia

In brief

This study investigates the effects of intravenous (IV) iron sucrose therapy on blood levels of Fibroblast Growth Factor 23 (FGF23, a protein that regulates the amount of phosphate in the body) in iron deficiency anemia in healthy participants, participants with Congestive Heart Failure (CHF, where the heart does not pump adequate blood supply to the body), participants with Chronic Kidney Disease (CKD, where the kidney function is reduced), and participants with CKD and CHF.

Key facts

Study ID
NCT03106298
Run by
Northwestern University
People needed
77
Starts
2015-12-18
Expected to finish
2018-08-01
Last updated by the study team
2019-03-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.